Savara (SVRA) Cash from Investing Activities (2010 - 2026)

Savara's (SVRA) quarterly Cash from Investing Activities came in at $38.8 million in Q1 2026, up 32.22% year-on-year from $29.3 million in Q1 2025, and up 141.45% on a QoQ basis from -$93.6 million in Q4 2025.

Savara (SVRA) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Savara (SVRA) has 17 years of Cash from Investing Activities data on file, last reported at $38.8 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 32.22% year-over-year to $38.8 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 58.0% increase from a year earlier, with the FY2025 full-year figure at -$18.4 million, up 53.83% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at $38.8 million, up from -$93.6 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for SVRA reached as high as $53.7 million in Q1 2022 and fell as low as -$98.2 million in Q3 2024.
  • Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of $17.9 million in 2024.
  • Across the five-year window, Cash from Investing Activities sank 4569.64% in 2022 and soared 3036.18% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$59.2 million in 2022, then soared by 111.1% to $6.6 million in 2023, then soared by 172.33% to $17.9 million in 2024, then slumped by 622.85% to -$93.6 million in 2025, then soared by 141.45% to $38.8 million in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were $38.8 million in Q1 2026, -$93.6 million in Q4 2025, and $21.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 Savara 1.39 Bn 1.39 Bn - 38.78 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 38.78 Mn
Mar 31, 2026 38.78 Mn
Dec 31, 2025 -93.56 Mn
Dec 31, 2025 -93.56 Mn
Sep 30, 2025 21.47 Mn
Sep 30, 2025 21.47 Mn
Jun 30, 2025 24.33 Mn
Jun 30, 2025 24.33 Mn
Mar 31, 2025 29.33 Mn
Mar 31, 2025 29.33 Mn
Dec 31, 2024 17.90 Mn
Dec 31, 2024 17.90 Mn
Sep 30, 2024 -98.17 Mn
Sep 30, 2024 -98.17 Mn
Jun 30, 2024 29.54 Mn
Jun 30, 2024 29.54 Mn
Mar 31, 2024 10.79 Mn
Mar 31, 2024 10.79 Mn
Dec 31, 2023 6.57 Mn
Dec 31, 2023 6.57 Mn